Monoamine Oxidase Inhibitor Drug Class List

Drugs in Drug Class: Monoamine Oxidase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	AB	RX	Yes	No	7,815,942		Y	Y
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	AB	RX	Yes	No	7,572,834		Y
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-002	May 16, 2006	AB	RX	Yes	Yes	7,815,942		Y	Y
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-002	May 16, 2006	AB	RX	Yes	Yes	7,572,834		Y

Monoamine Oxidase Inhibitor Market Analysis and Financial Projection

The Monoamine Oxidase Inhibitor (MAOIs) drug class is experiencing significant evolution in both market dynamics and patent activity, driven by therapeutic innovation and growing demand for neurological and psychiatric treatments.

Market Dynamics

1. Growth Drivers:

   • The global MAOIs market was valued at $1.4 billion in 2022 and is projected to reach $2.1 billion by 2030, growing at a CAGR of 5.2% [3][7]. MAO-B inhibitors specifically, used in Parkinson’s disease, are expected to grow from $1.2 billion in 2024 to $1.8 billion by 2033 (CAGR 5.5%)[4].
   • Rising prevalence of depression, anxiety, and neurodegenerative disorders (e.g., Parkinson’s disease) drives demand, coupled with an aging population and improved healthcare access in developing regions[1][3][6].
   • North America dominates with 40% market share, followed by Europe (30%) and Asia-Pacific (25%), where China’s rapid healthcare investments are accelerating adoption[1][6][11].

2. Key Players:
   Major pharmaceutical companies like Novartis, Pfizer, Eli Lilly, and Merck lead the market through R&D investments and strategic expansions. For example, Eli Lilly reported $28.7 billion in 2022 sales, with growth tied to new MAOI formulations[1][11].

3. Challenges:

   • Side effects and drug interactions limit MAOIs’ broader use, though newer selective inhibitors (e.g., MAO-B) aim to mitigate risks[4][14].
   • Competition from alternative antidepressants (e.g., SSRIs) and strict regulatory pathways complicate market entry[6][7].

---

Patent Landscape

1. Innovation Trends:

   • Selective MAO-B inhibitors dominate recent patents, targeting Parkinson’s disease, prostate cancer, and gliomas. For example:
     • US9771625B2 covers MAO-B inhibitors like selegiline for prostate cancer[10].
     • US6569470B2 includes MAO inhibitors for neurological disorders, emphasizing dopamine regulation[5].
   • Novel applications are emerging, such as Terran Biosciences’ oral DMT/5-MeO-DMT prodrugs that eliminate the need for MAOI co-administration[9].

2. Clinical Pipeline:

   • As of 2023, 54 MAO-B drugs are in development across 244 clinical trials, with companies like Viatris and Teva leading innovation[8][12].
   • Psilocybin analogs (e.g., Terran’s HCl/edisylate forms) and intranasal delivery systems (e.g., Tonix’s migraine treatment) highlight advances in formulation[9][15].

3. Strategic Collaborations:

   • Licensing and partnerships, such as Pfizer’s clinical trials and Zambon’s MAO-B research, aim to enhance drug efficacy and market penetration[1][11].

---

Future Outlook

• Personalized medicine and safer MAO-B inhibitors are expected to dominate R&D, addressing neurodegenerative and oncological conditions[13][14].
• Regulatory hurdles and patent disputes (e.g., CRISPR-related technologies) may slow progress, but expanding applications in chronic pain and inflammatory diseases offer growth avenues[16].

In summary, the MAOIs market is poised for sustained growth, fueled by therapeutic innovation and unmet clinical needs, while patent activity reflects a shift toward precision targeting and novel delivery mechanisms[1][9][14].

References

1. https://github.com/kathiestrine5ty/Market-Research-Report-List-1/blob/main/monoamine-oxidase-inhibitor-maois-market.md
2. https://patents.google.com/patent/US9771625B2/en
3. https://github.com/punamt99/Trends-Analysis-Network/blob/main/Monoamine%20Oxidase%20Inhibitor%20(MAOIs)%20Market%20Key%20Drivers%20and%20Forecast%202025-2032.md
4. https://www.verifiedmarketreports.com/product/monoamine-oxidase-b-market/
5. https://patents.google.com/patent/US6569470B2/en
6. https://markwideresearch.com/monoamine-oxidase-inhibitors-maois-market/
7. https://www.databridgemarketresearch.com/reports/global-monoamine-oxidase-mao-inhibitor-drugs-market
8. https://synapse.patsnap.com/blog/analysis-on-the-clinical-research-progress-of-mao-b-inhibitors
9. https://www.businesswire.com/news/home/20231208385528/en/Terran-Biosciences-Receives-Notice-of-Allowance-for-Four-US-Patents-Including-for-the-Worlds-First-New-Salts-and-Polymorphs-of-Psilocybin-potentially-enabling-future-505b2-pathway
10. https://patents.google.com/patent/US20220273588A1/en
11. https://www.360iresearch.com/library/intelligence/monoamine-oxidase-inhibitors-drugs
12. https://www.businesswire.com/news/home/20240306670920/en/Monoamine-Oxidase-Type-B-MAO-B-Inhibitors-for-7-MM-Market-Size-Target-Population-Competitive-Landscape-Forecasts-2034---ResearchAndMarkets.com
13. https://pubmed.ncbi.nlm.nih.gov/25399762/
14. https://pubmed.ncbi.nlm.nih.gov/29324067/
15. https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-by-the-united-states-patent-and-trademark-office-covering-the-intranasal-delivery-of-fda-approved-tosymra-to-treat-migraines
16. https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/